279 related articles for article (PubMed ID: 30982843)
21. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine.
Cady RK; Saper J; Dexter K; Cady RJ; Manley HR
Headache; 2015 Apr; 55(4):529-42. PubMed ID: 25828648
[TBL] [Abstract][Full Text] [Related]
23. Botulinum toxin type B for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
[TBL] [Abstract][Full Text] [Related]
24. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
25. Treatment of medication overuse headache: Effect and predictors after 1 year-A randomized controlled trial.
Carlsen LN; Rouw C; Westergaard ML; Nielsen M; Munksgaard SB; Bendtsen L; Jensen RH
Headache; 2021 Jul; 61(7):1112-1122. PubMed ID: 34325483
[TBL] [Abstract][Full Text] [Related]
26. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study.
Sandrini G; Perrotta A; Tassorelli C; Torelli P; Brighina F; Sances G; Nappi G
J Headache Pain; 2011 Aug; 12(4):427-33. PubMed ID: 21499747
[TBL] [Abstract][Full Text] [Related]
27. Treatment of withdrawal headache in patients with medication overuse headache: a pilot study.
Cevoli S; Giannini G; Favoni V; Terlizzi R; Sancisi E; Nicodemo M; Zanigni S; Bacchi Reggiani ML; Pierangeli G; Cortelli P
J Headache Pain; 2017 Dec; 18(1):56. PubMed ID: 28500492
[TBL] [Abstract][Full Text] [Related]
28. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
Mathew NT; Jaffri SF
Headache; 2009; 49(10):1466-78. PubMed ID: 19912346
[TBL] [Abstract][Full Text] [Related]
29. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
30. Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: A clinic-based prospective study.
Lee MJ; Lee C; Choi H; Chung CS
J Neurol Sci; 2016 Apr; 363():51-4. PubMed ID: 27000220
[TBL] [Abstract][Full Text] [Related]
31. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of mindfulness added to treatment as usual in patients with chronic migraine and medication overuse headache: a phase-III single-blind randomized-controlled trial (the MIND-CM study).
Grazzi L; D'Amico D; Guastafierro E; Demichelis G; Erbetta A; Fedeli D; Nigri A; Ciusani E; Barbara C; Raggi A
J Headache Pain; 2023 Jul; 24(1):86. PubMed ID: 37452281
[TBL] [Abstract][Full Text] [Related]
33. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study.
Rabe K; Pageler L; Gaul C; Lampl C; Kraya T; Foerderreuther S; Diener HC; Katsarava Z
Cephalalgia; 2013 Feb; 33(3):202-7. PubMed ID: 23093541
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.
Silberstein SD; Rapoport AM; Loupe PS; Aycardi E; McDonald M; Yang R; Bigal ME
Headache; 2019 Mar; 59(3):383-393. PubMed ID: 30450545
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
[TBL] [Abstract][Full Text] [Related]
36. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
[TBL] [Abstract][Full Text] [Related]
37. Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.
Cowan RP; Marmura MJ; Diener HC; Starling AJ; Schim J; Hirman J; Brevig T; Cady R
J Headache Pain; 2022 Sep; 23(1):115. PubMed ID: 36068494
[TBL] [Abstract][Full Text] [Related]
38. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
Mathew NT; Frishberg BM; Gawel M; Dimitrova R; Gibson J; Turkel C;
Headache; 2005 Apr; 45(4):293-307. PubMed ID: 15836565
[TBL] [Abstract][Full Text] [Related]
39. [Botulinum toxin A in chronic refractory migraine: premarketing experience].
Álvaro-González LC; Fernández-García JM; Aranzábal-Alustiza I; Castillo-Calvo B; Iriondo-Etxenagusia I; Rodríguez-Antigüedad A
Rev Neurol; 2012 Oct; 55(7):385-91. PubMed ID: 23011856
[TBL] [Abstract][Full Text] [Related]
40. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
Dodick DW; Silberstein SD; Lipton RB; DeGryse RE; Adams AM; Diener HC
Cephalalgia; 2019 Jul; 39(8):945-956. PubMed ID: 31112399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
